Recent Updates
Recently added Catalysts
EXEL Positive Sentiment

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Exelixis, Inc. announced its financial results for Q3 2026, highlighting progress in its corporate objectives. The company emphasized advancements in the cabozantinib franchise and preparations for zanzalintinib, which is expected to be a significant opportunity. Overall, the report reflects a positive trajectory for Exelixis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Reported strong financial results for Q3 2026.
  • Progress on cabozantinib franchise.
  • Preparation for zanzalintinib as a new opportunity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
2.5%
average across 6 past catalysts
Lead asset
Zanzalintinib
Phase 3 · Non-Clear Cell Renal Cell Carcinoma

Full Press Release Details

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael

Frequently Asked Questions

What were Exelixis' Q3 2026 financial results?

Exelixis reported strong financial results for the third quarter of 2026.

What is the cabozantinib franchise?

The cabozantinib franchise includes products developed by Exelixis for cancer treatment.

What is zanzalintinib?

Zanzalintinib is Exelixis' next potential franchise opportunity in development.

Who provided the corporate update?

Michael, presumably a company executive, provided the corporate update.

ShareAdd on Google
Tags: EXEL Exelixis cabozantinib zanzalintinib financial results pipeline development
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$1384M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ZanzalintinibPhase 3
Non-Clear Cell Renal Cell Carcinoma →

Catalyst track record

+21%
best trade around EXEL's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for EXEL.

See every catalyst's timing & PoA →